Oncolytic influenza A virus expressing interleukin‐15 decreases tumor growth in vivo

@article{Hock2017OncolyticIA,
  title={Oncolytic influenza A virus expressing interleukin‐15 decreases tumor growth in vivo},
  author={K. Hock and J. Laengle and I. Kuznetsova and A. Egorov and B. Hegedűs and B. Dome and T. Wekerle and M. Sachet and M. Bergmann},
  journal={Surgery},
  year={2017},
  volume={161},
  pages={735–746}
}
  • K. Hock, J. Laengle, +6 authors M. Bergmann
  • Published 2017
  • Biology, Medicine
  • Surgery
  • Background. Interleukin‐15 has become a promising molecule in the context of eliciting an effective, antitumor immune response because it is able to stimulate cells of the innate and adaptive immune system. Methods. We generated an interleukin‐15‐expressing oncolytic influenza A virus for the treatment of an established murine tumor model. Results. Our oncolytic influenza A virus produced large amounts of interleukin‐15 and induced proliferation and activation of human T cells in vitro… CONTINUE READING
    17 Citations
    Armed oncolytic viruses: A kick-start for anti-tumor immunity
    • 52
    • PDF
    A Recombinant Antibody-Expressing Influenza Virus Delays Tumor Growth in a Mouse Model.
    • 19
    Design and application of oncolytic viruses for cancer immunotherapy.
    • 15
    • PDF
    Tumor immunotherapy: New aspects of natural killer cells.
    • Y. Li, R. Sun
    • Medicine
    • Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
    • 2018
    • 31
    • PDF
    Cytokines in oncolytic virotherapy.
    Employing RNA viruses to fight cancer: novel insights into oncolytic virotherapy
    • 9
    The two-faces of NK cells in oncolytic virotherapy.

    References

    SHOWING 1-10 OF 56 REFERENCES
    Interferon resistance promotes oncolysis by influenza virus NS1‐deletion mutants
    • 64
    Endogenous expression of proteases in colon cancer cells facilitate influenza A viruses mediated oncolysis
    • 11
    Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus.
    • 51
    Interleukin 15 as a promising candidate for tumor immunotherapy.
    • 94
    Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
    • 458
    IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells
    • 489
    • PDF